Genfit says Covid-19 may not significantly delay NASH trial readout
Micrograph of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Credit: Nephron.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more